Published On: Fri, May 14th, 2021

Torrent Pharma signs licensing deal with Lilly for Covid drug baricitinib

Tagged with: | | | | | |

Torrent Pharmaceuticals (Torrent Pharma) has signed a licensing agreement with with an objective to bring the latter’s for treatment in India.

The royalty free, non-exclusive voluntary agreement enables Torrent Pharma to manufacture and distribute baricitinib along with Lilly’s other license partners.

According to Torrent Pharma, the agreement will help ensure a larger reach and access to Covid in India.

Torrent Pharma signs licensing deal with Lilly for Covid drug baricitinib

Torrent Pharma signs licensing deal with Lilly for Covid drug baricitinib. Image courtesy of Dr StClaire from Pixabay.

Baricitinib has been approved by India’s Central Drug Standard Control Organisation () for restricted emergency use in combination with .

The combination is indicated for the treatment of suspected or lab confirmed Covid-19 in hospitalized adults who need supplemental , invasive mechanical ventilation, or extracorporeal membrane oxygenation.

Aman Mehta – Chief Marketing Officer for Torrent Pharma said: “We are pleased to partner and work closely with Lilly to bring this treatment to market. This partnership further strengthens our efforts to help the nation fight the pandemic and provide quality treatment to patients.

“Torrent Group stands firmly committed to support the nation during this time of crisis.”

Related posts

Leave a comment

XHTML: You can use these html tags: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>